Towa Pharmaceutical Co., Ltd. (4553.T)
JPY 2808.0
(2.3%)
JPY 2808.0
(2.3%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 8.21 Billion | 2.54 Billion | 22.12 Billion | 12 Billion | 19.16 Billion | 19 Billion |
| Net Income | 16.17 Billion | 4.6 Billion | 22.24 Billion | 18.72 Billion | 20.7 Billion | 18.88 Billion |
| Depreciation & Amortization | 17.88 Billion | 19.4 Billion | 10.95 Billion | 10.42 Billion | 8.28 Billion | 8.34 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -26.94 Billion | -13.74 Billion | -3.1 Billion | -11.55 Billion | 233 Million | -1.55 Billion |
| Other non-cash items | 69.19 Billion | -7.72 Billion | -7.96 Billion | -5.58 Billion | -10.06 Billion | -6.67 Billion |
| Investing Cash Flow | -40.39 Billion | -30.28 Billion | -59.72 Billion | -9.1 Billion | -39.54 Billion | -3.99 Billion |
| Investments in PPE | -39.32 Billion | -30.46 Billion | -13.57 Billion | -9.87 Billion | -4.67 Billion | -11.35 Billion |
| Acquisitions | -1.56 Billion | -1.48 Billion | -45.4 Billion | -894 Million | -37.71 Billion | -207 Million |
| Investment purchases | -50 Million | -301 Million | -1 Million | -894 Million | -7.66 Billion | -25.41 Billion |
| Sales/Maturities of investments | - | 34 Million | 18 Million | 894 Million | 12.52 Billion | 33.99 Billion |
| Other Investing Activities | 550 Million | 1.93 Billion | -765 Million | 1.67 Billion | -2.02 Billion | -1 Billion |
| Financing Cash Flow | 35.4 Billion | 17.48 Billion | 46.54 Billion | 184 Million | 11.74 Billion | -809 Million |
| Debt repayment | -38.33 Billion | -12.26 Billion | -7.18 Billion | -17.74 Billion | -6.39 Billion | -4.24 Billion |
| Dividends payments | -2.95 Billion | -3.1 Billion | -2.41 Billion | -2.16 Billion | -2.06 Billion | -1.55 Billion |
| Common Stock Repurchased | - | - | 56.13 Billion | - | 20.2 Billion | - |
| Common Stock Issuance | - | - | 21 Million | - | 12 Million | - |
| Other Financing Activities | 24 Million | 32.84 Billion | -26 Million | 20.09 Billion | -1 Million | 4.99 Billion |
| Accounts receivables | -15.52 Billion | -1.59 Billion | 441 Million | -4.54 Billion | 2.77 Billion | -4.15 Billion |
| Accounts payables | -10.5 Billion | 6.55 Billion | 3.67 Billion | 2.45 Billion | 1.82 Billion | 4.65 Billion |
| Inventory | -6.28 Billion | -18.49 Billion | -7.95 Billion | -9.7 Billion | -4.3 Billion | -1.61 Billion |
| Other working capital | 5.37 Billion | -213 Million | 732 Million | 241 Million | -68 Million | -443 Million |
| Cash at beginning of period | 24.25 Billion | 32.83 Billion | 22.91 Billion | 18.71 Billion | 26.65 Billion | 11.51 Billion |
| Cash at end of period | 29.65 Billion | 24.25 Billion | 32.83 Billion | 22.91 Billion | 18.71 Billion | 26.65 Billion |
| Capital Expenditure | -39.32 Billion | -30.46 Billion | -13.57 Billion | -9.87 Billion | -4.67 Billion | -11.35 Billion |
| Effect of forex changes on cash | 2.16 Billion | 1.68 Billion | 975 Million | 761 Million | 689 Million | 943 Million |
| Net cash flow / Change in cash | 5.39 Billion | -8.57 Billion | 9.91 Billion | 4.2 Billion | -7.93 Billion | 15.14 Billion |
| Free Cash Flow | -31.11 Billion | -27.92 Billion | 8.55 Billion | 2.12 Billion | 14.49 Billion | 7.64 Billion |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 5.49 Billion | 16.17 Billion | 4.65 Billion | 4.56 Billion | 2.2 Billion | 4.75 Billion |
| Depreciation & Amortization | 4.73 Billion | 17.88 Billion | - | 4.55 Billion | 4.39 Billion | 4.26 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -2.09 Billion | -26.94 Billion | - | - | - | - |
| Other non-cash items | -14.02 Billion | 69.19 Billion | -4.65 Billion | -4.56 Billion | -2.2 Billion | -4.75 Billion |
| Investing Cash Flow | -1.61 Billion | -40.39 Billion | - | - | - | - |
| Investments in PPE | -1.24 Billion | -39.32 Billion | - | - | - | - |
| Acquisitions | - | -1.56 Billion | - | - | - | - |
| Investment purchases | - | -50 Million | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -371 Million | 550 Million | - | - | - | - |
| Financing Cash Flow | 11.4 Billion | 35.4 Billion | - | - | - | - |
| Debt repayment | -8.77 Billion | -38.33 Billion | - | - | - | - |
| Dividends payments | -1.4 Billion | -2.95 Billion | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 4.03 Billion | 24 Million | - | - | - | - |
| Accounts receivables | 525 Million | -15.52 Billion | - | - | - | - |
| Accounts payables | 672 Million | -10.5 Billion | - | - | - | - |
| Inventory | -2.8 Billion | -6.28 Billion | - | - | - | - |
| Other working capital | 185 Million | 5.37 Billion | - | - | - | - |
| Cash at beginning of period | 29.65 Billion | 24.25 Billion | - | 23.96 Billion | 30.81 Billion | 24.25 Billion |
| Cash at end of period | 35.01 Billion | 29.65 Billion | - | 30.7 Billion | 23.96 Billion | 30.81 Billion |
| Capital Expenditure | -1.24 Billion | -39.32 Billion | - | - | - | - |
| Effect of forex changes on cash | 1.25 Billion | 2.16 Billion | - | - | - | - |
| Net cash flow / Change in cash | 5.36 Billion | 5.39 Billion | - | 6.74 Billion | -6.85 Billion | 6.56 Billion |
| Free Cash Flow | -7.13 Billion | -31.11 Billion | - | 9.11 Billion | 8.79 Billion | 8.52 Billion |
IB
BTGGF
ABBOTINDIA
DICIND
CNTRF
SRS